ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis, The Lancet, vol.322, issue.8346, pp.355-362, 1983. ,
DOI : 10.1016/S0140-6736(83)90340-9
Reverse vaccinology, a genome-based approach to vaccine development, Vaccine, vol.19, issue.17-19, pp.2688-91, 2001. ,
DOI : 10.1016/S0264-410X(00)00554-5
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens, Vaccine, vol.30, issue.2, pp.87-97, 2012. ,
DOI : 10.1016/j.vaccine.2012.01.033
Assessing the Risk of Laboratory-Acquired Meningococcal Disease, Journal of Clinical Microbiology, vol.43, issue.9, pp.4811-4815, 2005. ,
DOI : 10.1128/JCM.43.9.4811-4814.2005
Risk of laboratory-acquired meningococcal disease, Journal of Hospital Infection, vol.49, issue.4, pp.282-286, 2001. ,
DOI : 10.1053/jhin.2001.1084
Safe laboratory handling of Neisseria meningitidis, Journal of Infection, vol.68, issue.4, pp.305-317, 2014. ,
DOI : 10.1016/j.jinf.2014.01.003
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans, Human Vaccines, vol.7, issue.6, pp.646-53, 2011. ,
DOI : 10.4161/hv.7.6.15482
Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates, Clinical and Vaccine Immunology, vol.18, issue.3, pp.483-489, 2011. ,
DOI : 10.1128/CVI.00304-10
Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers, Vaccine, vol.33, issue.29, pp.3322-3352, 2015. ,
DOI : 10.1016/j.vaccine.2015.05.027
Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age, The Pediatric Infectious Disease Journal, vol.33, issue.7, pp.760-766, 2014. ,
DOI : 10.1097/INF.0000000000000327
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, The Lancet Infectious Diseases, vol.13, issue.5, pp.416-441, 2013. ,
DOI : 10.1016/S1473-3099(13)70006-9
Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France, Vaccine, vol.34, issue.19, pp.2240-225027002504, 2016. ,
DOI : 10.1016/j.vaccine.2016.03.020
Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB, Vaccine, vol.34, issue.23, pp.2579-84, 2016. ,
DOI : 10.1016/j.vaccine.2016.04.009
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage, Vaccine, vol.31, issue.43, pp.4968-74, 2013. ,
DOI : 10.1016/j.vaccine.2013.08.006
Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus, Vaccine, vol.28, issue.31, pp.5023-3020493284, 2010. ,
DOI : 10.1016/j.vaccine.2010.05.014
Meningococcal surrogates of protection?serum bactericidal antibody activity, Vaccine, vol.23, issue.17-18, pp.2222-2229, 2005. ,
DOI : 10.1016/j.vaccine.2005.01.051